{"id":680948,"date":"2023-12-12T19:30:02","date_gmt":"2023-12-12T19:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680948"},"modified":"2023-12-12T19:30:02","modified_gmt":"2023-12-12T19:30:02","slug":"er-her2-ve-breast-cancer-market-latest-study-by-delveinsight-reveals-a-lucrative-investment-opportunity-and-growth-prospect-beigene-astrazeneca-cytomx-sanofi-eli-lilly-eqrx-gilead-roche","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/er-her2-ve-breast-cancer-market-latest-study-by-delveinsight-reveals-a-lucrative-investment-opportunity-and-growth-prospect-beigene-astrazeneca-cytomx-sanofi-eli-lilly-eqrx-gilead-roche_680948.html","title":{"rendered":"ER+\/ HER2 -ve Breast Cancer Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | BeiGene, AstraZeneca, CytomX, Sanofi, Eli Lilly, EQRx, Gilead, Roche"},"content":{"rendered":"
\n
\"ER+\/<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the ER+\/ HER2 -ve Breast Cancer Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of new therapies in the market.<\/div>\n

DelveInsight’s “ER+\/ HER2 -ve Breast Cancer Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the ER+\/ HER2 -ve Breast Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging ER+\/ HER2 -ve Breast Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current ER+\/ HER2 -ve Breast Cancer treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

ER+\/ HER2 -ve Breast Cancer: An Overview<\/strong><\/p>\n

ER+ (estrogen receptor-positive) and HER2- (human epidermal growth factor receptor 2-negative) breast cancer signifies a specific subtype of breast cancer characterized by the presence of estrogen receptors on the surface of cancer cells but an absence of HER2 protein overexpression. This subtype accounts for a significant proportion of breast cancer diagnoses. Symptoms of ER+\/HER2- breast cancer are similar to other breast cancer types, such as a lump or thickening in the breast, changes in breast size or shape, nipple changes, or skin dimpling. Diagnosis involves a series of tests including mammograms, ultrasounds, MRIs, and biopsies to confirm the cancer type and stage.<\/p>\n

Treatment for ER+\/HER2- breast cancer often involves a multidisciplinary approach. Hormone therapies like tamoxifen or aromatase inhibitors are typically employed to target estrogen receptors, blocking their activity or reducing estrogen levels in the body. Surgery (lumpectomy or mastectomy), radiation therapy, and chemotherapy might be recommended based on the stage and aggressiveness of the cancer. <\/p>\n

The burden of ER+\/HER2- breast cancer is significant due to its prevalence and the necessity for long-term treatments, potentially leading to significant emotional, physical, and financial strains on patients and healthcare systems. Research continues to explore targeted therapies and personalized medicine approaches to improve treatment outcomes and reduce the burden on individuals affected by this breast cancer subtype. Early detection through screenings and advancing treatment options are critical in addressing the growing burden of ER+\/HER2- breast cancer and improving survival rates.<\/p>\n

ER+\/ HER2 -ve Breast Cancer Market Key Facts<\/strong><\/p>\n